aren't MSB seeking approval from FDA with this?
Mesoblast Chief Medical Officer Dr Fred Grossman said: “We expect the mortality benefit observed in
this seminal Phase 3 trial will support a potential path for approval of rexlemestrocel-L in patients with
advanced chronic heart failure. We are planning to meet and discuss potential pathways to approval
based on mortality reduction with the United States Food and Drug Administration.”
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-166
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.090B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 94.0¢ | $551.8K | 579.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 68321 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 54215 | 51 |
View Market Depth
| Last trade - 11.59am 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |